clinical trial · NCT00780416
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Hepatitis CMP-424RibavirinPeginterferon Alfa-2bRibavirinPeginterferon Alfa-2b
brief summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
started
Nov 1, 2008
primary completion
Aug 1, 2010
completion
Aug 1, 2010
last updated
Jan 6, 2026
official title
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol